The Food and Drug Administration last week authorized marketing of a rapid diagnostic test to detect Ebola virus antigens in human blood from certain living individuals as well as samples from those recently deceased who are suspected to have died from Ebola. The OraQuick Ebola Rapid Antigen Test is the first rapid diagnostic test that the FDA has allowed to be marketed in the U.S. for the Ebola Virus Disease. “Today’s marketing authorization provides another important tool in the effort to fight Ebola,” said FDA Acting Commissioner Ned Sharpless, M.D. “…This marketing authorization may provide additional assurances to health care professionals seeking to use these types of rapid diagnostics. The ability to use this test to promptly make a presumptive Ebola diagnosis could help providers to more quickly isolate patients and begin treatments that can be potentially life-saving.”

Related News Articles

Headline
A New England Journal of Medicine study published yesterday found success in administering dostarlimab, an immunotherapy drug, to a group of 103 cancer…
Headline
Overall cancer death rates declined steadily among both men and women from 2018 through 2022, according to the National Institutes of Health's latest annual…
Headline
A study published April 14 by JAMA Network Open found that rates of pancreatic and colon cancer rose among young adults from 2000-2021. Researchers examined…
Headline
The Centers for Medicare & Medicaid Services April 10 released key priorities for new CMS Administrator Mehmet Oz, who was confirmed to the position April…
Headline
People under age 50 who consume cannabis are 6.2 times more likely to experience a heart attack than individuals who do not, according to a study published by…
Headline
A study published March 26 by the National Institutes of Health and the University of Oxford found that individuals who engaged in light and moderate-to-…